CervoMed data shows dementia drug effects

CervoMed presented new data at the AD/PD™ 2026 Scientific Conference reinforcing the positive effects of its drug neflamapimod in patients with Dementia with Lewy Bodies (DLB) who do not have co-existing Alzheimer's disease pathology. The analyses indicated that DLB patients with lower plasma pTau181 levels, suggesting earlier disease stages, showed particular benefit. This research offers promising insights into targeted treatments for specific patient subgroups within neurodegenerative diseases.